Welcome!

The Maryland and District of Columbia Society of Clinical Oncology, Inc. (“MDCSCO”) is committed to improving the quality and delivery of care in medical oncology in the State of Maryland and the District of Columbia. We promote appropriate standards of care in oncology and cooperate with investigators conducting cancer research.

In addition, we assist in the continuing education of oncologists and educate the public, the government, insurance carriers, and other health care providers about appropriate prevention of cancer and other therapeutic options for patients with cancer.

We encourage you to join more than 400 current members in providing the leadership in our progressive future. Click here to find out more about our membership.


Click to see the latest News & Publications

VIEWBOOK

Membership Benefits

Membership is Now FREE for
Professional
Members and for Allied
Professionals.

Click here to join!

 

IMPORTANT NOTICE TO ONCOLOGISTS

NO MORE DUES!

The Maryland and District of Columbia Society of Clinical Oncology now offers FREE professional memberships to physician oncologists. Click here for the flyer.

As a member, you get the following benefits:

  • Free attendance at ALL MDCSCO events.
  • A legislative voice on issues of high priority to the practice of oncology.
  • Being a member of one of the U.S.'s strongest ASCO state affiliates and representation at ASCO.
  • Representation at NCCN.
  • Opportunity to be considered for elected office and other leadership roles within MDCSCO.

Confirm your membership now!

 

NEW! Directive and order of the MD Secretary of Health!
There is a new requirement for Maryland physicians and health care providers to report suspected vaping illnesses to the local health departments, as well as for physicians and health care providers to take additional steps.
Click here for more information
Could Biosimilars Be Integrated into Alternative Payment Models?

Michael Kolodziej, MD, Vice President and Chief Innovation Officer at ADVI Health, Inc, addresses the role that biosimilars will have in alternative payment models in oncology.

Find out more

Cancer Pain Predicted by Lower Anxiety and Depression, Higher Social Support
A new study from the Levine Cancer Institute finds that patients with cancer who report higher levels of anxiety and depression experience more intense pain associated with their diseases.

Find out more

Nearly 60% of Blood Cancer Patients Covered by Medicare Delay or Forgo Treatment
Survival of older patients with blood cancers continues to improve as more effective, less toxic therapies are introduced. However, these lifesaving treatments often are expensive and many cancer patients face financial burdens caused by ever-increasing healthcare costs. In fact, according to a new study released October 21st by The Leukemia & Lymphoma Society (LLS), 59 percent of surviving blood cancer patients enrolled in traditional Medicare do not begin active treatment within three months of their diagnosis.

Find out more

ASCO Policy Brief Explains How Co-Pay Accumulators and Co-pay Maximizers Increase Cost of Cancer Care for Patients
Co-pay accumulators and co-pay maximizers have been an area of concern amongst State Affiliate Council members.  ASCO has created a new informational policy brief to help explain these programs and provide guidance regarding its position as an organization.  The brief can be accessed by clicking below.

Click here for more information

Report: Progress in Global Cancer Fight is Not Only Possible, but Achievable
The Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against cancer is not only possible, but achievable.

Find out more
Cancer Drugs Account for 27% of All New Drug Approvals in the US

Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows.

Click here for more

Sharing Hospital Outpatient Payment Proposal Maintains 340B Cuts, Addresses Price Transparency and Prior Authorization
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the proposal and will provide more information to members as soon as possible.

Click here for more.

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for more.

The Maryland Insurance Administration has developed a new webpage for health care providers with information and complaint processes related to:
1) prompt pay/clean claims;
2) retroactive denial of claims/recoupment;
3) credentialing; and
4) when you are not on a carriers HMO or provider panel.

Click here for more.



MDCSCO October 24, 2018
Membership and Awards Dinner
Award Recipient Sheila Ross


UPCOMING MEETINGS

2019 - SAVE THE DATES!

(See the event calendar for more info!)

December 4 - MDCSCO Industry Spotlight, Hanover, MD - Hotel at Arundel Preserve
Platinum, Emerald and Diamond Corporate members only.

December 7 - 9 – ASH Annual Meeting


ANNOUNCEMENTS


For Some Cancer Patients, Monitoring Symptoms Can Extend Their Lives
A growing body of research has found that people with cancer who are routinely prompted to answer questions about their symptoms may live months longer and have a higher quality of life than people who don’t track their symptoms as closely.

Find out more

American Cancer Society Announces New Video Series Created to Deliver Clinical and Emotional Support to Cancer Caregivers
To help support cancer caregivers, the American Cancer Society (ACS) has created a Caregiver Support Video Series that can answer caregivers' most-asked questions and address their biggest concerns.

Find out more

Community Needs More Time to Assess and Comment on CMMI’s Proposed Oncology Care First Model
Recently the Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (CMMI) released an informal request for information for a new model for value-based payments in oncology known as the “Oncology Care First” (OCF) model.  However, oncology practices and stakeholders need more time to adequately assess and provide detailed feedback on the OCF than the time CMMI has allotted.

Find out more

United Health and Optum 'Uniting Care and Coverage' in New Model
UnitedHealth Group and its Optum medical care provider business are rolling out a combined package of medical care and health insurance as they meld health benefits with the provision of healthcare services.

Find out more

Patients Need Protection From Surprise Medical Bills, Organizations Tell Congress
In a letter to leaders of the U.S. Senate and House of Representatives, ASCO, along with more than 100 other medical groups, urged Congress to protect patients from unanticipated, or “surprise,” medical bills that can occur when gaps in health insurance coverage lead them to receive care from out-of-network providers.

Find out more

New Survey Seeks Provider Input on Clinical Trial Enrollment
ASCO is participating in a joint initiative from the American Cancer Society's Cancer Action Network in conjunction with the Association of Community Cancer Centers and the Oncology Nursing Society.  Click below to access the survey.

Click here for the survey

Walmart to Measure Doctor Quality in Local Markets
Walmart is rolling out an effort to measure the quality of community doctors who treat tens of thousands of its employees in the retailer’s latest effort to make sure its workers get the right care, in the right place and at the right time.

Find out more

CMS to Collect 340B Drug Cost Information
The CMS issued a notice on September 26th that it will collect information from hospitals participating in the 340B drug discount program about the prices they pay for eligible drugs.

Click here for more
Educate and Support Your Patients with ASCO Answers Materials

Recently, State Affiliate presidents and executive directors received a mailing from Cancer.Net that included patient education materials that you and your members may find useful. These materials, along with additional resources that can be found on Cancer.Net give your patients ASCO-approved information on diagnosis, treatment, side effects, and psychosocial effects of cancer.  The ASCO Answers series includes fact sheets, booklets on specific topics in cancer care, and comprehensive, patient-friendly guides. These easy-to-read materials cover breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, cancer survivorship, caregiving, palliative care, managing cancer-related pain, advanced cancer care planning, and much more.  ASCO members save 20 percent.  All orders include free domestic shipping. 

Order printed copies online at the ASCO Store.

New Technology Add-on Payment: Impact on CAR T-cell Therapy Reimbursement
On August 2, the Centers for Medicare & Medicaid Services (CMS) released the Hospital Inpatient Prospective Payment System (IPPS) final rule for fiscal year (FY) 2020.

Click here for more.

CMS Expands CAR T-cell Therapy Coverage for Medicare Beneficiaries
The Centers for Medicare & Medicaid Services (CMS) announced that Medicare will now cover all Food and Drug Administration-approved Chimeric Antigen Receptor T-cell (CAR T-cell) therapy delivered in inpatient facilities.  This nationwide Medicare coverage increase for CAR T-cell therapy also opens the door for patients to receive treatment in outpatient health care facilities that are enrolled in FDS risk evaluation and mitigation strategies with expertise in delivering cellular therapies, and covers CAR T-cell therapy for off-label uses that are recommended by CMS-approved compendia.

Read more here